Expert Second Opinion: The Emerging Role of Immunotherapy and Targeted Treatment in Localized Non-Small Cell Lung Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The Phase III PACIFIC trial of consolidation therapy with durvalumab for patients with unresectable Stage III non-small cell lung cancer (NSCLC) without disease progression after definitive platinum-based concurrent chemoradiation therapy demonstrated which of the following outcomes with durvalumab in the intention-to-treat population?

    a. Improvement in progression-free survival (PFS) only

    b. Improvement in overall survival (OS) only

    c. Improvement in both PFS and OS

    d. No improvement in either PFS or OS

2. An interim analysis of the IMpower010 trial comparing atezolizumab to best supportive care after chemotherapy for patients with completely resected NSCLC found a significant improvement in disease-free survival with atezolizumab in which population of patients?

    a. Patients with Stage II to IIIA disease with PD-L1 less than 1%

    b. Patients with Stage II to IIIA disease with PD-L1 of 1% or higher

    c. All patients with Stage IB to IIIA disease

3. The Phase III CheckMate 816 trial evaluating nivolumab with platinum-doublet chemotherapy versus chemotherapy alone as neoadjuvant therapy for patients with resectable NSCLC demonstrated which of the following outcomes in terms of pathologic complete response rate?

    a. Significant improvement on the nivolumab arm

    b. Significant improvement with chemotherapy alone

    c. No significant difference between the study arms

4. Which of the following disease-free survival outcomes was reported from the Phase III ADAURA trial evaluating osimertinib as adjuvant therapy for patients with Stage IB to IIIA NSCLC with EGFR mutations?

    a. Significant benefit in comparison to placebo for patients with Stage IB to IIIA NSCLC

    b. Significant benefit in comparison to placebo for patients with Stage II and IIIA but not Stage IB disease

    c. No benefit in comparison to placebo in any subset